// App-Quantinova.ai

: Impact of reduced injected dose on the quantification of [18F]RO948 and [18F]Flortaucipir PET for in vivo tau pathology

Researchers

Presenter

  • Peter Young

Principal Investigators

  • Wesley P. Thomas

  • Jan Axelsson

  • Jakob Himmelmann

  • Pablo Aguilar Dominguez

  • Tomas Ohlsson

  • Oskar Hansson

  • Mark Lubberink

  • Sandra Sanabria Bohorquez

  • Anna Rieckmann

  • Suzanne L. Baker

  • Michael Schöll

Medical Centers

  • University of California Merced,

  • Lawrence Berkeley National Lab

  • Skane University Hospital

  • University of Gothenburg,

  • Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Moelndal, Sweden

  • University CollegeLondon, UK

  • Uppsala University,

  • Genentech Inc.

  • Wallenberg Centre for Molecular and Translational Medicine; University of Gothenburg,

  • Umea University,

  • Memory Clinic, Geneva University Hospitals

  • Clinical Memory Research Unit, Department of Clinical Sciences Malmoe, Lund University, Malmoe, Sweden

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • 18F-fluorodeoxyglucose

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved